Skip to main content
OpenTrials
Completed

NCT Number: NCT03546075

The Impact of Acute Trans-resveratrol Administration on Whole Body Metabolism During Cognitive Demand.

Background: Increased cerebral vaso-dilation during cognitive demand is hypothesised to improve cognitive performance due to an improved micronutrient status. Despite previous research demonstrating that oral resveratrol can modulate cerebral haemodynamics, this has not translated into expected improvements to cognitive performance in young, healthy populations. As the brain is the most metabolic organ in the body, even subtle changes to fuel utilization and overall energy expenditure are detectable during cognitive demand. The measurement of both overall energy expenditure and fuel utilization may provide further insight to the effects of resveratrol and whether oral supplementation of this polyphenol can provide clear, cognitive benefits in a young, healthy sample.

Objectives: The current study investigated the metabolic consequences of resveratrol on whole body metabolism and fuel oxidisation during cognitive performance.

Methods: This repeated measures, double blind, placebo controlled, balanced design required participants (N=24 for metabolic activity & N=26 for cognitive outcomes) to complete a serial subtraction demand battery at baseline, 45 minutes, 2 and 3 hours following 500 mg, 250 mg trans-resveratrol or inert placebo, on three separate occasions whilst connected to an on-line gas analysis system.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Cognitive Change

Age range

18 year–35 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participants who were able to give informed consent.
  • Those who didn't meet any of the exclusion criteria.
  • Those who took hormonal contraception (e.g. the pill, coil, implant, etc.) were still allowed to participate in the current study.

Exclusion criteria

  • Participants who smoke.
  • Participants below the age of 18 years or above 35 years at the time of giving consent to in role in the current study.
  • Participants with Body Mass Index outside the range of 18-35 kg/m2.
  • Participants with blood pressure greater than 140/90 HH/mg.
  • Participants with a history of neurological, vascular or psychiatric illness (excluding depressive illness and anxiety).
  • Participants with a current diagnosis of depression and / or anxiety.
  • Participants with learning difficulties: dyslexia, dyscalculia or colour blindness.
  • Participants with a visual impairment that cannot be corrected with glasses or contact lenses.
  • Participants with frequent migraines that require medication (more than or equal to 1 per month).
  • Participants with disorders of the blood.
  • Participants with a heart disorder.
  • Participants with diabetes.
  • Participants with a respiratory disorder that requires regular medication (Note: asthma sufferers who only take their medication occasionally/as required were eligible for this study).
  • Participants currently taking any prescription medications.
  • Participants who have habitually used dietary supplements within the last month (defined as more than 3 consecutive days or 4 days in total).
  • Participants with any food intolerances/sensitivities.
  • Participants with a history of renal or hepatic disease, or other severe diseases of the gastrointestinal tract (e.g., iron accumulation, iron utilization disorders, hypercalcaemia, hypercalciuria), that are likely to interfere with metabolism/absorption/secretion of the product under investigation.
  • Female participants who are currently pregnant, lactating or seeking to become pregnant.

Treatment and study plan

Resveratrol

Dietary Supplement

Placebo

Other

Primary outcomes

  1. Cognitive performance

    Time frame: 1 Hour

    Participants completed three Serial subtraction tasks (Serial 3, 7 & 17). Outcomes measured from all three of these tasks were the number correct entries and number of errors. The addition of the two outcomes can also provide a 'total' number of responses entered.

  2. Whole body metabolism

    Time frame: 1 Hour

    Whole body energy expenditure was measured via indirect calorimetry and was reported in calories burned per minute (Kcal / min).

  3. Fuel Oxidisation

    Time frame: 1 Hour

    Fuel oxidation was measured via indirect calorimetry and examined the rate of carbohydrate and fat oxidisation (both in grams per minute (g / min)).

Secondary outcomes

  1. Pulmonary gases

    Time frame: 1 Hour

    An on-line gas analysis system was used to measure oxygen intake and carbon dioxide excretion (both in litres per minute (L / min)) from the participant's expired pulmonary air.

Sponsors and collaborators

Lead sponsor

Northumbria University

Other

Registry information

Official study title

The Impact of Acute Trans-resveratrol Administration on Whole Body Metabolism During Cognitive Task Performance: a Double Blind, Randomised, Placebo-controlled Investigation.

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Jun 6, 2018
Registry last updated
Jun 6, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.